The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 26, 2017
Filed:
Jan. 07, 2015
Inserm (Institut National DE LA Sante ET DE LA Recherche Medicale, Paris, FR;
Universite Paul Sabatier Toulouse Iii, Toulouse, FR;
Centre Hospitalier Universitaire DE Toulouse, Toulouse, FR;
Universite DE Bourgogne, Dijon, FR;
Universite DE Rennes 1, Rennes, FR;
Universite Des Antilles ET DE LA Guyane, Pointe-a-Pitre, FR;
Ecole Des Hautes Etudes En Sante Publique (Ehesp), Rennes, FR;
Patrick Legembre, Rennes, FR;
Bruno Segui, Toulouse, FR;
Thierry Levade, Toulouse, FR;
Olivier Micheau, Dijon, FR;
INSERM (Institut National de la Sante et de la Recherche Medicale), Paris, FR;
Universite Paul Sabatier Toulouse III, Toulouse, FR;
Centre Hospitalier Universitaire de Toulouse, Toulouse, FR;
Universite de Bourgogne, Dijon, FR;
Universite de Rennes I, Rennes, FR;
Universit des Antilles et de la Guiyane, Pointe-a-pitre, FR;
Ecole des Hautes Etudes en Sante Publique (EHESP), Rennes, FR;
Abstract
The present invention relates to methods and pharmaceutical compositions for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells). In particular, the present invention relates to a method for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells) in a subject suffering from a cancer comprising the steps consisting of i) determining the expression level of at least one biomarker selected from the group consisting of soluble CD95L and EMT promoting factors in a sample obtained from the subject, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) administering the subject with a therapeutically effective amount of C16-ceramide or derivatives such as C16-sphingomyelin and C16-glycosphingolipids when the expression level determined at step i) is higher than the predetermined reference value.